Background: With a westernized diet the oxygenated products of renal prostaglandin synthesis are metabolites of the n–6 series and these are known to play important roles in several pathophysiological processes involved in calcium stone formation. As eicosapentaenoic acid (EPA) administration is effective for the prevention of hyperlipidemia and athelosclerosis, we suggest the use of EPA as a possible method of preventing calcium stone formation. Methods: We administered a highly purified preparation of 1,800 mg/day EPA to 29 patients for 36.4 ± 22.0 months after therapy for nephrolithiasis. We observed the urinary stone recurrence in these patients over the course of 8 years (before, during and after medication) and studied the preventive effect on the recurrence of nephrolithiasis. We analyzed the effect of EPA administration and compared the findings to those before and after administration. Results: The incidence rates of nephrolithiasis (times/year) before, during and after the administration of EPA were 0.2283, 0.0693 and 0.1742, respectively. The incidence rate of nephrolithiasis during the administration of EPA was significantly lower compared the findings to those before and after its administration (p < 0.05). Conclusion: The results suggest that EPA might reduce the risk of calcium stone formation.

Keywords:
Eicosapentaenoic acid, Nephrolithiasis, Calcium oxalate, Recurrent stone formation
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.